OverviewSuggest Edit

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. The Company's core strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats, and horses. Its lead product candidates are the intravenous, or IV, form of Zimeta (dipyrone injection), previously known as KIND-012, for the control of pyrexia (fever) in horses and Mirataz (mirtazapine transdermal ointment), formerly known as KIND-010, for management of weight loss in cats. In addition, the Company has other product candidates, including several biologics, in various stages of development.

TypePublic
Founded2013
HQBurlingame, US
Websitekindredbio.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2019)156(+7%)
Revenue (FY, 2019)$4.3 M(+117%)
Share Price (Oct 2020)$4.3
Cybersecurity ratingDMore

Key People/Management at Kindred Biosciences

Hangjun Zhan

Hangjun Zhan

Chief Scientific Officer
Wendy Wee

Wendy Wee

CFO
Katja Buhrer

Katja Buhrer

Chief of Staff, VP of Corporate Development and Investor Relations
Om Srivastava

Om Srivastava

Vice President of Pharmaceutical Development
Show more

Kindred Biosciences Office Locations

Kindred Biosciences has offices in Burlingame, San Diego and Wathena
Burlingame, US (HQ)
1555 Old Bayshore Hwy #200
Burlingame, US
863 Mitten Rd Suite 100 G
San Diego, US
591 Camino De La Reina #407
Wathena, US
1411 Oak St
Show all (4)

Kindred Biosciences Financials and Metrics

Kindred Biosciences Revenue

Kindred Biosciences's revenue was reported to be $4.26 m in FY, 2019
USD

Revenue (Q2, 2020)

163.0k

Gross profit (Q2, 2020)

136.0k

Gross profit margin (Q2, 2020), %

83.4%

Market capitalization (16-Oct-2020)

168.9m

Closing stock price (16-Oct-2020)

4.3

Cash (30-Jun-2020)

26.9m

EV

164.8m
Kindred Biosciences's current market capitalization is $168.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.0m4.3m

Cost of goods sold

324.0k587.0k

Gross profit

1.6m3.7m

Gross profit Margin, %

84%86%
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

640.0k515.0k1.2m1.1m603.0k163.0k

Cost of goods sold

110.0k92.0k169.0k139.0k3.6m27.0k

Gross profit

530.0k423.0k1.1m965.0k(3.0m)136.0k

Gross profit Margin, %

83%82%86%87%(493%)83%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.0m20.0m6.7m34.8m56.3m16.0m

Accounts Receivable

903.0k923.0k

Prepaid Expenses

797.0k1.7m2.5m

Inventories

1.9m1.8m3.6m4.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

36.5m9.3m8.3m5.4m14.8m4.5m9.6m16.0m13.3m19.9m36.9m43.6m44.5m85.4m70.0m68.6m32.0m39.2m14.0m26.9m

Accounts Receivable

2.1m492.0k242.0k275.0k937.0k801.0k244.0k263.0k

Prepaid Expenses

565.0k532.0k688.0k591.0k443.0k449.0k862.0k899.0k887.0k1.2m1.2m911.0k1.4m1.5m1.5m1.9m1.9m1.5m3.9m5.0m

Inventories

2.5m4.5m4.4m4.2m824.0k389.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(120.0k)(27.1m)(5.8m)(30.9m)(49.7m)(61.4m)

Depreciation and Amortization

146.0k155.0k475.0k805.0k2.5m

Inventories

(14.1m)16.0m(37.9m)(3.6m)(648.0k)

Accounts Payable

6.0k30.0k(710.0k)1.3m277.0k1.8m
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

Kindred Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

D

69/100

SecurityScorecard logo

Kindred Biosciences Online and Social Media Presence

Embed Graph

Kindred Biosciences News and Updates

Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart

SAN FRANCISCO, May 20, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart's oral vaccine candidate for...

Kindred Biosciences annonce que la Commission européenne a approuvé la pommade transdermique Mirataz® 20 mg/g pour chats présentant un faible appétit et une perte de poids

- Mirataz est le premier et le seul médicament approuvé dans l'Union européenne pour soigner les chats présentant un faible appétit et une perte de poids résultant de pathologies chroniques. SAN FRANCISCO, 21 décembre 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (Nasdaq : KIN), société...

Kindred Biosciences snags $50 mln debt facility

Kindred Biosciences, a biopharmaceutical company focused on pets, has secured a $50 million debt facility from Solar Capital Partners LLC and Cantor Fitzgerald & Co acted as sole lead arranger and financial adviser to KindredBio on this transaction.

Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program

SAN FRANCISCO, Sept. 10, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company developing novel drugs and biologics, today announced that it has been selected by the National Cancer Institute (NCI) as one of three contractors in...

Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational

SAN FRANCISCO, May 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Institutional Investor Conference taking place May 22nd in Beverly...

Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference

SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal Health Summit on February 25 in New York...
Show more

Kindred Biosciences Blogs

Kindred Biosciences Announces Plan to Strengthen its Strategic Position

San Francisco, California (June 8, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its strategic position. The company will prioritize its most attractive late stage programs and substan…

Event: Kindred Biosciences to Present at Stifel 2020 Virtual Jaws & Paws Conference

Wednesday, May 27, 2020 Presentation time: 12:05 p.m. ET Company Attendee: CEO Richard Chin Webcast URL: Click here For more information about this event, please see the press release. The post Event: Kindred Biosciences to Present at Stifel 2020 Virtual Jaws & Paws Conference appeared first on …

Kindred Biosciences to Present at Stifel 2020 Virtual Jaws & Paws Conference

San Francisco, California (May 13, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2020 Virtual Jaws & Paws Conference on May 27. Dr. Richard Chin, Chief Executive Officer, will present via…

Kindred Biosciences Announces First Quarter 2020 Financial Results

San Francisco, California (May 7, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2020 and provided updates on its programs. For the first quarter 2…

Event: Kindred Biosciences to Announce First Quarter 2020 Financial Results

Thursday, May 7, 2020 Time of Event: 4:30 p.m. Eastern time/1:30 p.m. Pacific time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID: 4476025 For more information about this event, please see the press release. The post Event: Kindred Bioscience…

Kindred Biosciences to Announce First Quarter 2020 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Thursday, May 7, 2020. San Francisco, California (April 23, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its…
Show more

Kindred Biosciences Frequently Asked Questions

  • When was Kindred Biosciences founded?

    Kindred Biosciences was founded in 2013.

  • Who are Kindred Biosciences key executives?

    Kindred Biosciences's key executives are Hangjun Zhan, Wendy Wee and Katja Buhrer.

  • How many employees does Kindred Biosciences have?

    Kindred Biosciences has 156 employees.

  • What is Kindred Biosciences revenue?

    Latest Kindred Biosciences annual revenue is $4.3 m.

  • What is Kindred Biosciences revenue per employee?

    Latest Kindred Biosciences revenue per employee is $27.3 k.

  • Who are Kindred Biosciences competitors?

    Competitors of Kindred Biosciences include WG Critical Care, Anatara Lifesciences and Napo Pharmaceuticals.

  • Where is Kindred Biosciences headquarters?

    Kindred Biosciences headquarters is located at 1555 Old Bayshore Hwy #200, Burlingame.

  • Where are Kindred Biosciences offices?

    Kindred Biosciences has offices in Burlingame, San Diego and Wathena.

  • How many offices does Kindred Biosciences have?

    Kindred Biosciences has 4 offices.